Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ethinyl Estradiol+ Levonorgestrel · 1 trial · 1 indication
Cmax of Ethinyl Estradiol and Levonorgestrel.
Tmax of Ethinyl Estradiol and Levonorgestrel.
β of Ethinyl Estradiol and Levonorgestrel.
t1/2 of Ethinyl Estradiol and Levonorgestrel.
AUCt of Ethinyl Estradiol and Levonorgestrel.
AUCinf of Ethinyl Estradiol and Levonorgestrel.
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| Period 1 & 2 | EXPERIMENTAL | In Period 1, participants will receive a single dose of ethinyl estradiol and levonorgestrel. In Period 2, participants will receive multiple daily doses of ABBV-722 and a single dose of ethinyl estradiol and levonorgestrel. |
| Name | Type | Description |
|---|---|---|
| Ethinyl Estradiol + Levonorgestrel | DRUG | Oral |
| ABBV-722 | DRUG | Oral |
Inclusion Criteria: * Laboratory values meet the criteria specified in the protocol. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG). Exclusion Criteria: * History of an...
Ethinyl Estradiol + Levonorgestrel is a combination of two hormones used in a Phase 1 clinical trial to assess its drug levels in healthy adult female participants. The study, NCT07502417, was conducted in the United States and has been completed. It is an investigational drug combination being studied for research purposes.
Ethinyl Estradiol + Levonorgestrel is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company conducted a Phase 1 clinical trial to evaluate the effect of another drug, ABBV-722, on the levels of ethinyl estradiol and levonorgestrel in healthy female participants.
Ethinyl Estradiol + Levonorgestrel is in Phase 1 clinical development. The single trial listed, NCT07502417, is a Phase 1 study that has been completed. It is an investigational combination and is not approved by regulatory authorities for any indication.
Ethinyl Estradiol + Levonorgestrel has one completed clinical trial, NCT07502417, titled "A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants." The study enrolled 15 healthy female participants aged 18 years and older in the United States.
Yes, Ethinyl Estradiol + Levonorgestrel is the same as ethinyl estradiol/levonorgestrel. These are alternative names for the same combination of hormones. The drug is being studied in a Phase 1 clinical trial by AbbVie Inc. to assess its levels in healthy adult female participants.